Markets & Finance

Vertex Pharmaceuticals is acquiring Crinetics Pharmaceuticals for $85.00 per share in an all-cash deal with no contingent value rights, funded by existing cash and a $4.5 billion bridge loan, targeting a Q3 2026 close. The price implies an enterprise value of roughly $8.8 billion after Crinetics' approximately $1.2 billion in net cash, and values a company with just $8 million in 2025 revenue primarily on the projected $5 billion peak-sales potential of PALSONIFY, the first FDA-approved once-daily oral acromegaly therapy, plus a Phase 3 Cushing's disease candidate. Antitrust risk appears limited because Vertex's existing pipeline in cystic fibrosis, sickle cell disease, and kidney disease shares no indication, mechanism, or commercial overlap with Crinetics' endocrine franchise.

US Treasury yields rose uniformly by 5 basis points on July 7, 2026, with the 10-year note closing at 4.53% and the 30-year approaching 5%, driven primarily by Fed Governor Waller's call for flexible rather than rigid forward guidance and geopolitical shipping disruptions in the Strait of Hormuz. The move outpaced simultaneous rises in German Bunds and Japanese JGBs, which gained only 4 and 1 basis points respectively, indicating the pressure was largely US-specific. Despite the yield surge, the VIX closed at 15.84 and high-yield credit spreads held at 2.72%, signaling markets treated the move as a policy recalibration rather than a systemic risk event.

S&P Dow Jones Indices added Marvell Technology and Flex Ltd. to the S&P 500 effective June 22, 2026, replacing Pool Corporation and Campbell's, with the three largest index ETFs alone implying roughly $10.45 billion in mechanical buying for Marvell and $2.54 billion for Flex. The addition pushed the semiconductor sector's weight in the S&P 500 to 19.7 percent by June 30, up from approximately 5 percent in 2020 and more than double its dot-com-era peak. The S&P effective date preceded the Russell reconstitution implementation by seven trading days, materially separating the two largest mechanical rebalancing events in U.S. equities.